Company Description
Scorpius Holdings, Inc., through its subsidiary Scorpius BioManufacturing, operates as an integrated contract development and manufacturing organization.
The company engages in clinical and commercial drug substance manufacturing; and release and stability testing activities.
It is also involved in the provision of various process development services, including upstream and downstream development and optimization, and analytical method development solutions, as well as cell line development, testing, and characterization services.
The company was formerly known as NightHawk Biosciences, Inc. and changed its name to Scorpius Holdings, Inc. in February 2024.
Scorpius Holdings, Inc. was incorporated in 2008 and is based in Morrisville, North Carolina.
| Country | United States |
| Founded | 2008 |
| IPO Date | Jul 24, 2013 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 84 |
| CEO | Jeffrey Wolf |
Contact Details
Address: 627 Davis Drive, Suite 300 Morrisville, North Carolina 27560 United States | |
| Phone | 919 240 7133 |
| Website | scorpiusbiologics.com |
Stock Details
| Ticker Symbol | SCPX |
| Exchange | NYSEAMERICAN |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001476963 |
| ISIN Number | US42237K4094 |
| Employer ID | 26-2844103 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Jeffrey Alan Wolf J.D. | Founder, Chairman, President and Chief Executive Officer |
| William L. Ostrander | Chief Financial Officer, Controller and Secretary |
| Dr. Justin Stebbing FRCP, FRCPath, M.A., M.D., Ph.D. | Chief Medical Advisor and Member of Scientific and Clinical Advisory Board |
| Colonel George E. Peoples Jr., F.A.C.S., M.D. | Chief Medical Advisor |
| Ania Szymanska | Site Head of Quality |
| Joe Payne | President and Chief Operating Officer of Scorpius BioManufacturing |
| Nicole Temple | Senior Manager and Head of Program Management |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jan 21, 2025 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| Jan 17, 2025 | 8-K | Current Report |
| Jan 16, 2025 | 8-K | Current Report |
| Dec 27, 2024 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| Dec 27, 2024 | 8-K | Current Report |
| Dec 23, 2024 | 424B3 | Prospectus |
| Dec 20, 2024 | EFFECT | Notice of Effectiveness |
| Dec 20, 2024 | DEF 14A | Other definitive proxy statements |
| Dec 18, 2024 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| Dec 11, 2024 | D | Notice of Exempt Offering of Securities |